Results 201 to 210 of about 184,985 (285)
Objective This study aimed to determine if program format (in‐person, virtual, or hybrid) results in differences in 3‐month outcomes of pain, function, quality of life, self‐efficacy, and chair stands in a hip/knee osteoarthritis‐management program. Methods A secondary analysis of the Good Life with osteoArthritis in Denmark (GLA:D) Canada database was
Jill Van Damme +7 more
wiley +1 more source
Lactation accommodations at continuing medical education courses: Attendee attitudes, needs, preferences, and experiences. [PDF]
Carey P +8 more
europepmc +1 more source
Evaluation of continuing medical education in Al-qasim, saudi arabia.
Omer A Al-Yahia +3 more
openalex +1 more source
AOA continuing medical education [PDF]
openaire +3 more sources
Objective This study aims to describe the frequency and timing of physician referrals to physical therapists (PTs) and other treatments prescribed over 12 months in patients with recent onset of knee osteoarthritis (KOA). The study also aims to identify determinants of early PT referrals.
Samannaaz S. Khoja +4 more
wiley +1 more source
A Mixed-Methods Evaluation of a Maternal Child Health Nurse Education Programme Using Moore's Outcomes Framework for Continuing Medical Education. [PDF]
King E, Lim L, Gray A.
europepmc +1 more source
Continuing Medical Education in the Post COVID-19 Pandemic Era.
Blomberg D +6 more
europepmc +1 more source
Objective We conducted formative research aimed at identifying solutions that address inequitable health outcomes in lupus due to adverse social determinants of health (SDoH). Methods We conducted a search for keywords, which provided insights into potential solutions and initiatives underway. An advisory panel of lupus experts iteratively reviewed the
Joy Buie +11 more
wiley +1 more source
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan +7 more
wiley +1 more source

